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Proteomic Strategies in the Search
of New Biomarkers in Atherothrombosis
José Tuño´n, MD,*‡ José Luis Martı´n-Ventura, PHD,†‡ Luis Miguel Blanco-Colio, PHD,†‡
Óscar Lorenzo, PHD,†‡ Juan Antonio Lo´pez, PHD,§ Jesús Egido, MD†‡
Madrid, Spain
Extensive research has focused on the identification of novel plasma biomarkers to improve our ability to predict
cardiovascular events in atherothrombosis. However, classical techniques can only assess a limited number of
proteins at a time. Given that plasma contains more than 900,000 proteins, this approach will be extremely
time-consuming. Novel proteomic approaches make it possible to compare the expression of hundreds of pro-
teins in several samples in a single experiment. The classical approach consists of separation of proteins on a
2-dimensional gel followed by protein identification with mass spectrometry, although new complementary gel-
free techniques are emerging. We can thus compare protein expression in an atherosclerotic plaque with that in
a normal artery or study plasma proteins in patients with atherothrombosis as compared with healthy subjects.
For such approaches, it is not necessary to study the published data to select potential biomarkers. However,
because the number of patients that can be studied with most of these techniques is limited, what is really im-
portant is the design of the studies, assessing carefully what kind of patients should be included to obtain valid
conclusions. Clinicians should thus play a key role in this design along with the basic scientist. In this article, we
review several proteomic strategies carried out by our group and others, and we make a call for collaboration
between clinicians and experts in proteomics. This collaboration could greatly increase the likelihood of identify-
ing new prognostic biomarker panels in atherothrombosis and other cardiovascular disorders. (J Am Coll Cardiol
2010;55:2009–16) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.036o
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sdentifying subjects at risk of developing an acute ischemic
vent remains one of the great challenges of cardiovascular
edicine. Classical approaches, such as the presence of cardio-
ascular risk factors, are unable to accurately predict cardiovas-
ular events (CVE). In recent years, plasma biomarkers have
een the focus of extensive study. Although many potential
olecules have been described, the results have not been
onsistent enough (1), and most of them are not used in clinical
ractice.
Plasma contains more than 900,000 proteins (2). Given
hat it takes approximately 10 years from biomarker discov-
ry to the development of a commercial kit (2), testing each
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010, accepted January 25, 2010.f these proteins individually by traditional techniques
ight take an eternity. Moreover, when several studies
bout new potential biomarkers with negative results are
ublished, investigators might be discouraged about the
sefulness of biomarkers. However, given the large number
f proteins present in the plasma, the reporting of negative
esults for a few potential biomarkers does not invalidate
his approach. Moreover, these studies are usually based
n individual biomarkers, whereas the use of a panel of
iomarkers reporting information of several mechanisms
nvolved in this disorder might be more effective. There-
ore we need new methods to screen for novel biomarkers
n atherothrombosis.
ew Proteomic Approaches
he standard techniques used for the assessment of proteins
n biological specimens, such as enzyme-linked immunosor-
ent assay, determine only the levels of individual proteins.
roteomic approaches combine 2-dimensional electro-
horesis (2DE) and mass spectrometry (MS), allowing
undreds of proteins in a given sample tissue to be assayed
imultaneously (3) (Fig. 1). In 2DE proteins are first
eparated according to their charge by isoelectric focusing in
dimension. Then, they are separated further in the second
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Proteomics and Biomarkers in Atherothrombosis May 11, 2010:2009–16dimension according to molecu-
lar mass (4). After staining, gels
of different samples are analyzed
with computer software to detect
differentially expressed protein
spots. Finally, MS determines the
molecular masses of the proteins
identifying them (5). This tech-
nique requires the conversion of
the proteins into gas-phase ions,
with various procedures. The ions
are separated according to the
mass/electrical charge ratio (m/z)
with a mass analyzer and analyzed
with highly sensitive detectors (5).
Basically, 2 types of MS are
used. In matrix-assisted laser de-
sorption ionization time of flight
(MALDI-TOF), ionization is
achieved by mixing the sample
with organic compounds that crys-
tallize to form a matrix. A laser
pulse vaporizes the peptides,
which are accelerated in an electri-
cal field and are sent to a flight
tube, at the end of which the
detector is located. For a given
electrical acceleration voltage, the
time of flight (TOF) to the detec-
or is proportional to m/z. Small molecules fly faster than large
nes. The group of peptide masses obtained from its digestion
Abbreviations
and Acronyms
2DE  2-dimensional
electrophoresis
CVE  cardiovascular
events
HDL  high-density
lipoprotein
HSP  heat-shock protein
ICAT  isotope-coded
affinity tags
iTRAQ  isobaric tags for
relative and absolute
quantification
LC  liquid chromatography
MALDI-TOF  matrix-
assisted laser desorption
ionization time of flight
MS  mass spectrometry
NSTEACS  non–ST-
segment elevation acute
coronary syndrome
SELDI-TOF  surface-
enhanced laser desorption/
ionization time of flight
mass spectrometry
sTWEAK  soluble tumor
necrosis factor-like weak
inducer of apoptosis
Figure 1 Classical Proteomic Approach
(Left) Protein separation by 2-dimensional electrophoresis. (Right) Protein identifi
MALDI-TOF  matrix-assisted laser desorption ionization time of flight; SDS-PAGE 
sion, from Vivanco et al. (13).s compared with the theoretical masses of the peptides that
ould be produced upon digestion of the proteins present in
he databases (6), to identify a protein. The second type of
pectrometer vaporizes the sample directly from the liquid
hase by electrospray ionization or nebulizer (7) with an
lectrical field to disperse the sample. For this technique, a
iquid chromatography (LC) separation step is usually em-
loyed before detection to provide a much more reliable
rotein identification—even with impure protein prepara-
ions—than MALDI-TOF. A peptide can then be selected
nd broken up in a collision chamber. The resulting fragments
re sent to the detector, and their masses are obtained. The
equence of the peptide or a short sequence tag is determined
y analysis of the fragmentation spectrum. These sequences are
hen used for database searching. Fragmentation spectra are
herefore highly informative and can be powerful tools for
haracterizing post-translational modifications and for de novo
equencing of unknown proteins.
In addition to 2DE/MS, other platforms have been devel-
ped. Gel-free “shotgun” proteomic techniques use LC sepa-
ation procedures with automated tandem MS and are being
pplied for the analysis of complex proteomic samples, where a
hole proteome is digested with or without prior protein
eparation. The typical approach is called multidimensional
rotein identification technology (Fig. 2). This technique
dentifies proteins in complex mixtures, including basic, highly
ydrophobic, or extreme molecular weight proteins, which are
ifficult to resolve on 2DE gels. It has greater resolution than
el-based approaches but requires rigorous statistical methods,
iven the large amount of data analyzed.
by mass spectrometry. IEF  isoelectrofocus; IPG  immobilized pH gradient;
um dodecyl sulfate polyacrylamide gel electrophoresis. Adapted, with permis-cation
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May 11, 2010:2009–16 Proteomics and Biomarkers in AtherothrombosisQuantitative analysis can be performed with LC-MS/MS
fter differential isotopic or isobaric labeling of the proteins
r peptides from 2 cell extracts, which are simultaneously
uantified and identified (8,9). These approaches can be
pplied in different steps along the separation process and
nclude stable isotope labeling by amino acids in cell culture,
sotope-coded affinity tags (ICAT), tandem mass tags, and
ore recently, isobaric tags for relative and absolute quan-
ification (iTRAQ). For example, in the iTRAQ method
agging is carried out on primary amines, eliminating the
ependence on cysteine-containing peptides, as in ICAT
abeling, yielding complementary results to ICAT. The
CAT method identifies a higher proportion of signaling
roteins, whereas iTRAQ detects a larger percentage of
ibosomal proteins and transcription factors (9). These
ethods are compatible with sample fractionation to reduce
rotein complexity, allowing the measurement of low-
bundance proteins. Also, they could potentially be used as
he basis for automated, quantitative, and global proteome
nalysis. However, most label-based quantification ap-
roaches have important limitations, mainly complex sam-
le preparation and handling, increased sample concentra-
ion, incomplete labeling, or reduced protein coverage.
herefore, classic label-free quantification is currently being
mproved to overcome some of these issues for quantifying
omplex protein mixtures in LC-MS–based strategies
10,11). These methods use direct comparison of peptide
eak areas between LC-MS runs without any isotopic
abeling. As a result, they do not require costly reagents and
ave the advantage of simplicity in sample preparation (10).
Alternative approaches have been used in recent years. In
rray technologies, multiple binding antibodies are placed
n a platform. However, it allows us to search only for
re-specified proteins for which antibodies are available.
oreover, the space available on the platform limits the
umber of antibodies that can be used. This approach might
e useful to confirm the data obtained with the techniques
escribed previously. With surface-enhanced laser desorp-
Figure 2 Nanoscale LC-MS/MS Setup
Multidimensional protein identification technology column: a reverse phase (RP) an
in the emitter tip. High voltage is applied in front of the column. Samples move in
cess. (2) Peptides elute onto the SCX–pre-column while contaminants are washed
in a single salt application step. (4) Peptides are separated on the RP-phase acco
spectrometer (MS), which ionizes the peptides, deflects them, and detects the ionion/ionization time of flight mass spectrometry (SELDI- sOF), we might identify a pattern of MS peaks (known as
proteomic fingerprint”) in a given disorder. This approach
s suitable for completing characterization of a proteome,
lthough it cannot directly identify differentially expressing
roteins. Finally, MALDI imaging uses MALDI for re-
ording the spatial distribution of proteins and peptides
ithin tissue sections mounted together with a MALDI
atrix and shows selected masses as color images. Figure 3
hows an overview of proteomic approaches.
A thorough description of proteomic techniques is be-
ond the scope of this review and may be found in references
2,3,11–13). However, we will focus on the design of studies
sing proteomic approaches. Clinicians should be familiar
ith this field, because they have the potential to collaborate
ith proteomic specialists to improve the design of future
esearch to answer clinical problems of relevance to patients
ith atherothrombosis.
roteomics Versus Genomics
t is important to study proteins, because they reflect what
s happening in the organism. Humans have 30,000 to
0,000 genes (14), only approximately twice the number of
ess complex organisms, such as worms. However, a single
ene might yield different proteins, due to alternative
plicing of transcripts and protein post-translational
hanges. Thus, although the genome is stable and gives
nformation about the potential of an organism, the pro-
eome is dynamic and reflects the biological processes that
re taking place in that organism. Both approaches are
omplementary and, along with transcriptomics and
etabolomics (which study the transcripts and the metab-
lites, respectively), integrate the so-called “omic” sciences
Fig. 4).
roteomic Strategies in the Development of
iomarkers in Atherothrombosis: In Vitro Studies
ells involved in atherothrombosis can be cultured and
rong cation exchange (SCX)–pre-column are followed by an RP-separation phase
first phase (1) and are trapped on RP–pre-column during the loading pro-
. (3) Trapped peptides elute from the SCX–pre-column onto RP-separation column
o their hydrophobicity and elute in an acetonitrile gradient directly into a mass
a are delivered to a computer for analysis. LC  liquid chromatography.d a st
to the
away
rding t
s. Dattimulated with pro-atherothrombotic factors, and their
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Proteomics and Biomarkers in Atherothrombosis May 11, 2010:2009–16rotein extracts can undergo proteomic analysis (Fig. 5).
ollowing this strategy, Fach et al. (15) compared the effects
f stimulation of monocytic cells with oxidized and native
ow-density lipoprotein. They used multidimensional LC
nd tandem MS, identifying 59 overexpressed proteins and
7 underexpressed ones. Within the overexpressed proteins
here were fatty-acid binding proteins, chitinase-like en-
ymes, cyclophilins, cathepsins, proteoglycans, urokinase-
ype plasminogen activator receptor, and macrophage scav-
nger receptor. Coppinger et al. (16) showed by shotgun
roteomics that platelets release more than 300 proteins
fter being activated by thrombin, many of which were not
reviously attributed to these cells. Among these were
ecretogranin III, a monocyte chemoattractant precursor;
yclophilin A, a vascular smooth muscle cell growth factor;
nd calumenin, an inhibitor of the vitamin K epoxide
eductase-warfarin interaction. Given that platelets are
Figure 3 Overview of Proteomics Strategies
Four major proteomics approaches are outlined. Differential in-gel electrophoresis
Samples of proteins from 2 experimental conditions are labeled with 2 fluorescent
the sensitivity and the reproducibility of the 2DE process. ESI  electrospray ioniz
tive and absolute quantification; SELDI-TOF  surface-enhanced laser desorption/
acids in cell culture; other abbreviations as in Figure 1.nucleated cells and contain very small amounts of messen- cer ribonucleic acid, proteomics is better than genomics and
ranscriptomics for assessing their status.
However, primary cell culture itself induces phenotypic
hanges. Therefore, the proteome of cultured cells will yield
nformation on the potential of these cells to respond to
therogenic stimuli rather than on the exact proteome
xpressed by them within the arterial wall. The ideal
pproach to explore the cell proteome in atherosclerosis
ould be to separate different cell types from atheroma with
aser microdissection.
Other in vitro strategies might help us to characterize
otential biomarkers. For example, low high-density lipopro-
ein (HDL) is associated with a higher incidence of athero-
clerosis. However, torcetrapib, a drug that increases HDL
lasma levels, enhances mortality (17). This leads to a debate
bout what HDL components should be measured. Recently,
hotgun proteomics has shown that HDL is composed of
represents an improvement in comparative 2-dimensional electrophoresis (2DE).
mixed together and run on a single 2DE gel, reducing variability and improving
HPLC  high-performance liquid chromatography; iTRAQ  isobaric tags for rela-
ion time of flight mass spectrometry; SILAC  stable isotope labeling by amino(DIGE)
dyes,
ation;
ionizatomplement regulatory proteins, protease inhibitors, and
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May 11, 2010:2009–16 Proteomics and Biomarkers in Atherothrombosiscute-phase response proteins, among others (18). Further-
ore, HDL3 from patients with coronary artery disease was
electively enriched in apolipoprotein E, suggesting that HDL
omposition might be different in this disorder. Similarly,
eat-shock protein (HSP)27 has anti-inflammatory and anti-
poptotic effects and could be a candidate biomarker. With
DNA
mRNA m
NUCLEUS
CELL
Transcription
Transport
Genomics
~40,000 genes
Transcripto
~250,000 g
Figure 4 The “Omic” Sciences
Genomics investigates the whole genome (deoxyribonucleic acid [DNA]) and its fun
messenger ribonucleic acid (mRNA). From mRNA transcripts, proteins are translate
olites are examined by metabolomics.
Figure 5 Proteomic Strategies for the Study of Atherothrombos
Abbreviations as in Figures 1 and 3.DE, Trott et al. (19) found that phosphorylated HSP27 but
ot the hypophosphorylated form decreased expression of
ycling proteins and ubiquitination enzymes in endothelial and
ascular smooth muscle cells. This suggests that phosphory-
ated HSP27 might be an important regulator of vascular cell
roliferation and could be a good candidate biomarker.
 mRNA
Protein
mature Protein
Translation
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Proteomics
~106 genes
M
etabolom
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l relations. From DNA, ribonucleic acid is transcripted. Transcriptomics studies
teomics analyzes the protein expression profile. Endogenous synthesized metab-ature
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Proteomics and Biomarkers in Atherothrombosis May 11, 2010:2009–16roteomic Analysis of Atherosclerotic Tissue
hole tissue. Atheroma can be explored by proteomics.
owever, it is very heterogeneous, and the results might
ary according to whether we analyze the lipid core or the
brous cap. Laser capture microdissection allows extraction
f specific tissue sections, reducing sample heterogeneity.
evertheless, the subsequent proteomic analysis is limited
o techniques with extremely high analytical sensitivity, due
o the reduced amount of protein obtained (10,000 cells
re usually collected). We can compare atheroma with
ormal arterial wall, and we can also explore the effect of
ifferent therapies. Also, in human atheroma we can search
or differences between the proteome of those who develop
VE and that of those who remain stable during follow-up.
ith this approach, Pasterkamp et al. (20) identified
steopontin as a candidate biomarker. After 3 years of
ollow-up in a validation cohort, they confirmed that high
steopontin expression was associated with the incidence of
VE. Such an approach might help identify new proteins
ith prognostic value, helping us to select patients for more
ntensive therapies. Additional studies are required to con-
rm whether plasma levels of the proteins discovered by this
ethod are related to prognosis. This approach would be
seful for the whole population and not just for those with
ndarterectomy.
Imaging MS is another emergent technology for the
tudy of whole tissue. The MS is applied to thin-tissue
ryostat sections deposited onto MALDI plaques or
rotein chip surfaces (SELDI), evidencing the spatial
istribution of proteins in tissue sections (Fig. 5). With
his technique, we have shown the presence of high
mounts of non-esterified fatty acids and vitamin E
round intimal areas with high cholesterol accumulation
n human atheroma (21).
ecretome. Another problem working with whole tissue is
hat many constitutive proteins could mask others that have
ltered expression and that could play an important role in
his disease. An alternative strategy is culturing atheroscle-
otic plaques and analyzing the supernatant, obtaining the
roteins secreted by the cells (i.e., the secretome). In this
ay we can detect candidate biomarkers released from the
ascular wall into the blood, providing information about
he processes taking place in the vascular tree.
Combining this approach with 2DE/MS, we found that
omplex human carotid atherosclerotic plaques released 202
roteins to the supernatant, noncomplex plaques secreted
52, and healthy arteries released only 42 (22). The super-
atant of cultured atheroma showed a decrease in HSP27
evels as compared with that of normal arteries (23). We
onfirmed that the levels of this antiapoptotic and anti-
nflammatory protein were lower in the plasma of patients
ith carotid atherosclerosis than in healthy subjects. How-
ver, in healthy women we found that HSP27 plasma levels
ere not related to the incidence of CVE (24). tApplying SELDI-TOF to this strategy, we also detected
ower levels of soluble tumor necrosis factor-like weak
nducer of apoptosis (sTWEAK) (25), a protein involved in
poptosis, proliferation, and inflammation. Surprisingly,
TWEAK plasma levels were lower in patients with carotid
therosclerosis than in healthy subjects and showed a
egative correlation with carotid intima-media thickness.
he coexistence of abnormal sTWEAK levels and an
nflammatory environment predicted mortality in patients
n hemodialysis (26).
Finally, we can also add drugs to the medium to assess
heir effect on the secretome. Adding atorvastatin to
ultured complicated atherosclerotic plaques reverted
6% of the proteins whose expression was altered to
ontrol values (27).
he Study of Blood by Proteomic Approaches
lood cells. In this setting, early treatment of the sample is
ecessary to avoid protein degradation. We studied the pro-
eome of circulating monocytes in patients with non–ST-
egment elevation acute coronary syndrome (NSTEACS)
28). With 2DE/MS, we detected 17 proteins whose
xpression was altered, as compared with expression in
ubjects with stable coronary artery disease. The number
f proteins with abnormal expression decreased with
ime. At 6 months, the proteome of the circulating
onocytes was similar to that of subjects with stable
oronary artery disease, suggesting that, by this time, the
rocesses that triggered NSTEACS had finished. We
ound, among the proteins showing abnormal expression,
ecreased levels of antiatherogenic proteins, such as
araoxonase I and HSP70, and anti-inflammatory pro-
eins, such as protein disulfide isomerase. In contrast,
here was overexpression of mature cathepsin D, with
ro-atherogenic effects, and enolase I, involved in mac-
ophage transformation into foam cells.
With a similar approach we showed that atorvastatin 80
g/day affected the expression of 20 proteins in NSTEACS
atients as compared with moderate statin therapy (29).
mong them, there was a normalization of the decreased
xpression of HSP70, paraoxonase I, annexin I—which has
nti-inflammatory properties—and annexin II—involved in
pontaneous fibrinolysis.
Although the study of circulating cells might uncover
ew proteins involved in atherothrombosis, cell isolation
nd protein extraction are time-consuming. Also, samples
annot be stored for more than 4 h, due to protein
egradation. Therefore studying plasma levels of the de-
cribed proteins might be more appropriate, because plasma
ay be obtained by simple centrifugation of the blood
ample and stored until processing.
lasma. Study of the plasma with proteomic tools faces
ertain problems. Only 9 proteins represent 90% of the
rotein mass in plasma. Therefore, it is necessary to improve
he techniques to separate these high-abundance proteins
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May 11, 2010:2009–16 Proteomics and Biomarkers in Atherothrombosishat might mask low-abundance proteins. Another pending
ssue is the enhancement of the resolution of the techniques.
urrently, by combining the results from different pro-
eomic platforms, more than 3,000 proteins have been
etected in plasma (2,30)—far less than the 900,000 pro-
eins hypothesized to be present. Nevertheless, many of
hese proteins are different forms of immunoglobulin G,
roduced throughout the person’s history of immune events.
hese proteins hold a high similarity in sequence, and most
f them are unlikely to be biomarkers of atherothrombosis,
eing possible to deplete them with an affinity-based
ethod. Thus, the number of potential biomarkers will be
ell below this number, probably approximately several
housand. Another relevant question is whether to use
erum or plasma samples. Although it is possible to study
erum, plasma contains the proteins of the coagulation
ascade. Given the leading role of this system in triggering
cute ischemic events, plasma would be the preferred type of
ample, provided we can adequately isolate the proteins of
nterest from the more abundant proteins.
With 2DE/MALDI-TOF, Brea et al. (31) found high
evels of plasma haptoglobin and serum amyloid A to be
ssociated with atherothrombotic rather than with cardio-
mbolic stroke. Although these data need to be confirmed
n larger populations, they might be useful in the manage-
ent of these patients, because cardioembolic stroke should
e treated with anticoagulants. With the same approach,
ateos-Ca´ceres et al. (32) found a reduction in the con-
entration of several isoforms of alpha1-antitrypsin and
polipoprotein A-I and an increase in heavy chains of
brinogen and gamma-immunoglobulin in the plasma of
atients with acute coronary syndrome.
esigning Proteomic Research:
ole of the Clinician
s we have seen, new proteomic approaches provide re-
earchers with a powerful tool in the search for new
iomarkers. However, the clinician has a key role to play to
void spending time and money conducting irrelevant stud-
es with flawed approaches. For instance, studying plasma
roteins in patients during an acute ischemic event might
eveal new proteins implicated in atherogenesis that could
e potential biomarkers. However, clinical cardiologists
now that some of the proteins detected might simply be
he consequence of myocardial necrosis and not play a
ausative role in plaque thrombosis. Therefore it would
robably be more interesting to focus on NSTEACS
atients rather than on those with ST-segment elevation
yocardial infarction, because necrosis is more severe in this
ondition.
Probably, the best approach in the future will be to study
he plasma from patients with atherothrombosis and to
ollow them for a period of time, comparing the proteome
f those who develop recurrences of CVE with that of
atients who remain stable during follow-up. Because pro- meomic techniques are costly (Table 1) and time-consuming,
tudying large numbers of patients is not possible. In this
etting, matching of cases and control subjects by relevant
linical variables not limited to age and sex is essential to
void bias leading to confounding results. Also, the cardi-
logist should carefully choose the end points of the study.
or instance, although heart failure is a dreaded event for
hese patients, its development might be the result of
yocardial damage secondary to a previous infarction rather
han reflecting the progression of atherothrombosis. How-
ver, once the experiment is completed, it is possible to find
umerous proteins differing between stable patients and
hose with recurrences. To select a panel with the minimal
roup of proteins retaining the maximal discriminative
ower for use in clinical practice, we can use several criteria.
irst, we must take into account the strength of statistical
ignificance by choosing those with lower “p” values. Sec-
nd, we must focus on proteins whose function is potentially
elated to the disorder studied. For this purpose, collabora-
ive efforts among clinicians, scientists, and bioinformatics
xperts are warranted. Third, selecting proteins with stable
lasma levels is also important. The clinician might help in
esigning new experiments to test the stability of the plasma
evels of the proteins detected by proteomics.
Once the proteomic approach has yielded a candidate
iomarker panel in studies with a limited number of patients
exploration cohort), the next step consists of testing this
anel in a validation cohort with conventional methods. In
hese studies, larger populations might be included, being
gain of prime importance to control for clinical variables
hat could influence the outcome. Validation studies will
onfirm whether the selected biomarker panel really adds
rognostic value to the clinical variables used routinely in
he clinical practice.
onclusions
dentifying biomarkers by conventional methods is a time-
onsuming task. Proteomics allows us to explore the expres-
ion of hundreds of proteins involved in atherosclerosis with
theroma specimens, circulating blood cells, plasma, or
erum. We might use strategies comparing samples from
atients with healthy control subjects, from patients receiv-
pproximate Costs of Someasic Proteomic TechniquesTable 1 Approximate Costs of SomeBasic Proteomic Techniques
Technique Cost
2DE $150–240
DIGE $1,200
Protein identification (MALDI-TOF) $60–150
Protein identification nanoLC-MS/MS $600
MudPIT $2,000
atrix-assisted laser desorption ionization time of flight (MALDI-TOF) costs are displayed/spot
dentified. For the remaining techniques, costs are shown/sample analyzed except for differential
n-gel electrophoresis (DIGE) (2 samples). These prices are orientative and might vary in different
aboratories.
2DE 2-dimensional electrophoresis; LC-MS/MS liquid chromatography-mass spectrometry/
ass spectrometry; MudPIT  multidimensional protein identification technology.
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eveloping CVE with those remaining stable at follow-up.
iven the large number of proteins present in the plasma
nd atheroma, this might be the only effective way to select
group of them that might improve our prediction of the
ccurrence of CVE. The proteomic approach does not
equire previous knowledge of the proteins to be assessed.
ather, patient selection, the strategy to follow, and the
ind of samples to be analyzed are critical to obtain the
aximal yield from this technique. Moreover, the number
f patient samples to be analyzed is limited by the complex-
ty and high cost of this approach. In this setting, matching
f the clinical characteristics of the populations to be
ompared is of great importance to avoid drawing wrong
onclusions. Clinicians should then be encouraged to col-
aborate in multidisciplinary studies with proteomic experts
n this task, to enhance the ability of cardiovascular medi-
ine to predict which populations are at high risk of
therothrombotic events. Prevention programs could then
ocus on these high-risk populations with the most intensive
herapies to decrease the incidence of CVE.
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